GenMark Diagnostics Inc. [NASDAQ: GNMK] surged by $0.97 during the normal trading session on Wednesday and reaching a high of $15.15 during the day while it closed the day at $15.11. The company report on September 22, 2020 that Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Lisa Giles and Robert Wills to its Board of Directors, effective October 1, 2020. Ms. Giles will serve as a member of the Audit Committee of the Board and Dr. Wills will serve as a member of the Nominating & Corporate Governance Committee of the Board.
“On behalf of the entire Board of Directors, it is a pleasure to welcome Lisa and Rob, two highly accomplished industry veterans, to our team,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “Their collective experience across a range of diverse strategic roles will be highly instrumental as we continue to advance our Phase 3 program of etripamil for the treatment of paroxysmal supraventricular tachycardia, prepare for commercialization, and build out our pipeline. I look forward to working with them and leveraging their unique expertise.”.
GenMark Diagnostics Inc. stock has also gained 6.41% of its value over the past 7 days. However, GNMK stock has declined by -19.15% in the 3 months of the year. Over the past six months meanwhile, it has gained 150.17% and gained 214.14% year-on date.
The market cap for GNMK stock reached $1.08 billion, with 66.53 million shares outstanding and 55.49 million shares in the current float. Compared to the average trading volume of 1.33M shares, GNMK reached a trading volume of 1275990 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about GenMark Diagnostics Inc. [GNMK]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GNMK shares is $20.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GNMK stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Needham have made an estimate for GenMark Diagnostics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 05, 2020. While these analysts kept the previous recommendation, Needham raised their target price from $15 to $19. The new note on the price target was released on July 08, 2020, representing the official price target for GenMark Diagnostics Inc. stock. Previously, the target price had yet another raise from $11 to $15, while Needham kept a Buy rating on GNMK stock.
The Average True Range (ATR) for GenMark Diagnostics Inc. is set at 0.82, with the Price to Sales ratio for GNMK stock in the period of the last 12 months amounting to 8.52. The Price to Book ratio for the last quarter was 11.11, with the Price to Cash per share for the same quarter was set at 1.86.
GNMK stock trade performance evaluation
GenMark Diagnostics Inc. [GNMK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.41. With this latest performance, GNMK shares gained by 34.37% in over the last four-week period, additionally plugging by 150.17% over the last 6 months – not to mention a rise of 168.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GNMK stock in for the last two-week period is set at 61.86, with the RSI for the last a single of trading hit 69.01, and the three-weeks RSI is set at 56.89 for GenMark Diagnostics Inc. [GNMK]. The present Moving Average for the last 50 days of trading for this stock 14.42, while it was recorded at 14.22 for the last single week of trading, and 10.05 for the last 200 days.
GenMark Diagnostics Inc. [GNMK]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and GenMark Diagnostics Inc. [GNMK] shares currently have an operating margin of -47.50 and a Gross Margin at +32.50. GenMark Diagnostics Inc.’s Net Margin is presently recorded at -53.79.
Return on Total Capital for GNMK is now -52.75, given the latest momentum, and Return on Invested Capital for the company is -60.44. Return on Equity for this stock declined to -207.18, with Return on Assets sitting at -46.32. When it comes to the capital structure of this company, GenMark Diagnostics Inc. [GNMK] has a Total Debt to Total Equity ratio set at 631.28. Additionally, GNMK Total Debt to Total Capital is recorded at 86.33, with Total Debt to Total Assets ending up at 68.88. Long-Term Debt to Equity for the company is recorded at 616.14, with the Long-Term Debt to Total Capital now at 84.25.
Reflecting on the efficiency of the workforce at the company, GenMark Diagnostics Inc. [GNMK] managed to generate an average of -$108,352 per employee. Receivables Turnover for the company is 6.22 with a Total Asset Turnover recorded at a value of 0.86.GenMark Diagnostics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.20 and a Current Ratio set at 5.70.
Earnings per share (EPS) analysis for GenMark Diagnostics Inc. [GNMK] stock
With the latest financial reports released by the company, GenMark Diagnostics Inc. posted -0.2/share EPS, while the average EPS was predicted by analysts to be reported at -0.19/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -5.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GNMK.
GenMark Diagnostics Inc. [GNMK]: Insider Ownership positions
There are presently around $1,038 million, or 97.40% of GNMK stock, in the hands of institutional investors. The top three institutional holders of GNMK stocks are: FMR LLC with ownership of 10,451,263, which is approximately 14.643% of the company’s market cap and around 4.30% of the total institutional ownership; CONSONANCE CAPITAL MANAGEMENT LP, holding 6,894,481 shares of the stock with an approximate value of $104.18 million in GNMK stocks shares; and BLACKROCK INC., currently with $81.71 million in GNMK stock with ownership of nearly 26.511% of the company’s market capitalization.
Positions in GenMark Diagnostics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 109 institutional holders increased their position in GenMark Diagnostics Inc. [NASDAQ:GNMK] by around 36,477,258 shares. Additionally, 49 investors decreased positions by around 19,937,605 shares, while 9 investors held positions by with 12,272,443 shares. The mentioned changes placed institutional holdings at 68,687,306 shares, according to the latest SEC report filing. GNMK stock had 57 new institutional investments in for a total of 22,775,956 shares, while 17 institutional investors sold positions of 9,725,537 shares during the same period.